AbbVie (ABBV) experienced a slew of significant events as described in recent news. The most crucial events include the company's
acquisition of Celsius Therapeutics and Landos Biopharma, which are expected to contribute significantly to strengthening AbbVie's portfolio in Inflammatory and Autoimmune Diseases. The
FDA expanded the company's Epkinly label in Follicular Lymphoma, lending a positive outlook to AbbVie's fight against cancer. Notably, AbbVie's Duopa successor was turned down by the FDA for the second time, pushing back progress on their Parkinson's disease therapy. Consequently, investor sentiment has fluctuated, with some entities growing or decreases their holdings in AbbVie stock. In terms of dividends, AbbVie has declared a quarterly figure.
Financial reports indicate strong earnings for AbbVie, with robust commitments to dividend payments and a solid performance in the stock market, which seems to outpace the S&P500. Finally, late-stage studies on
multiple myeloma drug have also commenced.
Abbvie ABBV News Analytics from Fri, 02 Feb 2024 08:00:00 GMT to Sun, 30 Jun 2024 15:01:03 GMT -
Rating 6
- Innovation 3
- Information 8
- Rumor -5
